| 0.2388 -0.014 (-5.5%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.49 | 1-year : | 0.68 |
| Resists | First : | 0.42 | Second : | 0.58 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.15 | Second : | 0.12 |
| MAs | MA(5) : | 0.24 |
MA(20) : | 0.25  |
| MA(100) : | 0.29 |
MA(250) : | 0.57 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 18.1 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 1.25 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QLGN ] has closed above bottom band by 33.0%. Bollinger Bands are 109% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.27 - 0.27 | 0.27 - 0.27 |
| Low: | 0.23 - 0.23 | 0.23 - 0.24 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Wed, 24 Jul 2024
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 8% - Defense World
Mon, 15 Jul 2024
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
Mon, 15 Jul 2024
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? - InvestorPlace
Fri, 12 Jul 2024
Why Is Qualigen (QLGN) Stock Up 141% Today? - InvestorPlace
Thu, 11 Jul 2024
Qualigen Therapeutics Secures Loan and Expands Equity - TipRanks
Thu, 11 Jul 2024
Qualigen Therapeutics secures $2M through Senior Note issuance - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 571 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.5 % |
| Return on Equity (ttm) | -841.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|